可溶性 AβPPβ 作为痴呆症阿尔茨海默病的生物标志物的血浆水平。

Plasma Levels of Soluble AβPPβ as a Biomarker for Alzheimer's Disease with Dementia.

机构信息

Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

Department of Psychiatry, University Hospital of Rion, University of Patras, Patras, Greece.

出版信息

J Alzheimers Dis. 2019;69(1):83-90. doi: 10.3233/JAD-181088.

DOI:10.3233/JAD-181088

PMID:30909232

Abstract

Cost- and time-effective markers of Alzheimer's disease (AD), reliable and feasible at the population level are urgently needed. Soluble amyloid-β protein precursor β (sAβPPβ) in plasma has attracted scientific attention as a potential AD biomarker candidate. Here we report that plasma sAβPPβ levels in patients with AD dementia and typical for AD cerebrospinal fluid (CSF) biomarker profiles (N = 33) are significantly lower (p < 0.01) than those of cognitively healthy elderly individuals without AD (N = 39), while CSF sAβPPβ levels did not differ between the studied groups. This provides further evidence for the potential of sAβPPβ in plasma as an AD biomarker candidate.

摘要

目前迫切需要具有成本效益且能够有效反映阿尔茨海默病（AD）的标志物，且这种标志物还需要具有在人群水平上的可靠性和可行性。血浆可溶性淀粉样蛋白前体β（sAβPPβ）作为一种有潜力的 AD 生物标志物候选物，已经引起了科学界的关注。在这里，我们报告称，AD 痴呆症患者的血浆 sAβPPβ水平以及具有典型 AD 脑脊液（CSF）生物标志物特征的患者（N=33）显著低于认知健康的无 AD 老年个体（N=39）（p<0.01），而两组患者的 CSF sAβPPβ水平没有差异。这进一步证明了血浆 sAβPPβ作为 AD 生物标志物候选物的潜力。